Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial

医学 多西紫杉醇 恩扎鲁胺 临床终点 前列腺癌 内科学 抗雄激素 氟他胺 人口 肿瘤科 中期分析 比卡鲁胺 睾酮(贴片) 随机对照试验 泌尿科 癌症 雄激素受体 环境卫生
作者
Christopher J. Sweeney,Andrew Martin,Martin R. Stockler,Stephen Begbie,Leanna Cheung,Kim N.,Simon Chowdhury,Mark Frydenberg,Lisa G. Horvath,Anthony M. Joshua,Nicola Jane Lawrence,Gavin Marx,John McCaffrey,Ray McDermott,Margaret McJannett,Scott North,Francis Parnis,Wendy R. Parulekar,David Pook,M. Neil Reaume
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:24 (4): 323-334 被引量:184
标识
DOI:10.1016/s1470-2045(23)00063-3
摘要

Background The interim analysis of the ENZAMET trial of testosterone suppression plus either enzalutamide or standard nonsteroidal antiandrogen therapy showed an early overall survival benefit with enzalutamide. Here, we report the planned primary overall survival analysis, with the aim of defining the benefit of enzalutamide treatment in different prognostic subgroups (synchronous and metachronous high-volume or low-volume disease) and in those who received concurrent docetaxel. Methods ENZAMET is an international, open-label, randomised, phase 3 trial conducted at 83 sites (including clinics, hospitals, and university centres) in Australia, Canada, Ireland, New Zealand, the UK, and the USA. Eligible participants were males aged 18 years or older with metastatic, hormone-sensitive prostate adenocarcinoma evident on CT or bone scanning with 99mTc and an Eastern Cooperative Oncology Group performance status score of 0–2. Participants were randomly assigned (1:1), using a centralised web-based system and stratified by volume of disease, planned use of concurrent docetaxel and bone antiresorptive therapy, comorbidities, and study site, to receive testosterone suppression plus oral enzalutamide (160 mg once per day) or a weaker standard oral non-steroidal antiandrogen (bicalutamide, nilutamide, or flutamide; control group) until clinical disease progression or prohibitive toxicity. Testosterone suppression was allowed up to 12 weeks before randomisation and for up to 24 months as adjuvant therapy. Concurrent docetaxel (75 mg/m2 intravenously) was allowed for up to six cycles once every 3 weeks, at the discretion of participants and physicians. The primary endpoint was overall survival in the intention-to-treat population. This planned analysis was triggered by reaching 470 deaths. This study is registered with ClinicalTrials.gov, NCT02446405, ANZCTR, ACTRN12614000110684, and EudraCT, 2014-003190-42. Findings Between March 31, 2014, and March 24, 2017, 1125 participants were randomly assigned to receive non-steroidal antiandrogen (n=562; control group) or enzalutamide (n=563). The median age was 69 years (IQR 63–74). This analysis was triggered on Jan 19, 2022, and an updated survival status identified a total of 476 (42%) deaths. After a median follow-up of 68 months (IQR 67–69), the median overall survival was not reached (hazard ratio 0·70 [95% CI 0·58–0·84]; p<0·0001), with 5-year overall survival of 57% (0·53–0·61) in the control group and 67% (0·63–0·70) in the enzalutamide group. Overall survival benefits with enzalutamide were consistent across predefined prognostic subgroups and planned use of concurrent docetaxel. The most common grade 3–4 adverse events were febrile neutropenia associated with docetaxel use (33 [6%] of 558 in the control group vs 37 [6%] of 563 in the enzalutamide group), fatigue (four [1%] vs 33 [6%]), and hypertension (31 [6%] vs 59 [10%]). The incidence of grade 1–3 memory impairment was 25 (4%) versus 75 (13%). No deaths were attributed to study treatment. Interpretation The addition of enzalutamide to standard of care showed sustained improvement in overall survival for patients with metastatic hormone-sensitive prostate cancer and should be considered as a treatment option for eligible patients. Funding Astellas Pharma.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
甜羊羊发布了新的文献求助10
刚刚
1秒前
1秒前
www发布了新的文献求助10
1秒前
wanghuifen123完成签到,获得积分10
2秒前
2秒前
搜集达人的应助被MY采纳,获得10
2秒前
FashionBoy的应助被努力的土豆泥采纳,获得10
3秒前
共享精神的应助被ZY采纳,获得10
3秒前
wanci的应助被17866157506采纳,获得10
4秒前
4秒前
jinjin发布了新的文献求助10
4秒前
4秒前
珍珠糖完成签到 ,获得积分10
5秒前
yyw10304发布了新的文献求助10
5秒前
6秒前
CHA完成签到,获得积分10
6秒前
6秒前
木田完成签到,获得积分10
6秒前
氧化钙发布了新的文献求助10
7秒前
清水飒完成签到,获得积分20
7秒前
Vino发布了新的文献求助10
7秒前
8秒前
orixero的应助被就很好采纳,获得10
8秒前
想要成为FPS糕手完成签到,获得积分10
8秒前
8秒前
orixero的应助被未小未采纳,获得10
8秒前
淼淼完成签到,获得积分10
9秒前
不太重的稻草人完成签到,获得积分10
10秒前
哈哈哈完成签到,获得积分10
10秒前
12秒前
代桃完成签到,获得积分10
12秒前
General发布了新的文献求助10
12秒前
junglebag发布了新的文献求助10
13秒前
13秒前
13秒前
JamesPei的应助被1250gg采纳,获得10
14秒前
轻松婴发布了新的文献求助10
14秒前
15秒前
辞清发布了新的文献求助10
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Monte Cassino in the Middle Ages Volume I 310
JUSTIFICATION OF SMALL-SCALE MODELS: AN INDUSTRY PERSPECTIVE 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8157522
求助须知:如何正确求助?哪些是违规求助? 9553431
关于积分的说明 21714472
捐赠科研通 7746618
什么是DOI,文献DOI怎么找? 3426800
关于科研通互助平台的介绍 2551516
邀请新用户注册赠送积分活动 2470765